Treating age-related multimorbidity: the drug discovery challenge

Christos Ermogenous; Charlotte Green; Thomas Jackson; Michael Ferguson; Janet M Lord

doi:10.1016/j.drudis.2020.06.016

Treating age-related multimorbidity: the drug discovery challenge

Drug Discov Today. 2020 Aug;25(8):1403-1415. doi: 10.1016/j.drudis.2020.06.016. Epub 2020 Jun 20.

Authors

Christos Ermogenous¹, Charlotte Green², Thomas Jackson¹, Michael Ferguson², Janet M Lord³

Affiliations

¹ MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
² Drug Discovery Unit, University of Dundee, Dundee, UK.
³ MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK; NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK. Electronic address: j.m.lord@bham.ac.uk.

PMID: 32574698
DOI: 10.1016/j.drudis.2020.06.016

Abstract

Advanced age is the major risk factor for multimorbidity. Current clinical practice treats the individual age-related diseases, resulting in polypharmacy. Thus, targeting the biological processes that drive ageing could prevent both multimorbidity and polypharmacy.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Aging* / genetics
Animals
Biomarkers
Disease Hotspot
Drug Discovery*
Humans
Multimorbidity*

Substances

Biomarkers

Abstract

Publication types

MeSH terms

Substances

Grants and funding